1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)

A Sacher,R Grant,M Makarem,J Knox,P Ohashi,P Rogalla,L Eng,M-S Tsao,N Leighl,E Chen,B Wang,P Bradbury,F.A Shepherd,M Allen,L Corke,G Liu,S Lau,E Elimova,R.W-J Jang,Rachel Garonce-Hediger

doi:10.1016/j.annonc.2022.07.1943

1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)

A Sacher, R Grant + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1943

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: University Health Network

#Non-squamous Non-small Cell Lung Cancer #Immune Microenvironment In Hepatocellular Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) constitute leading global causes of cancer-related death. PD-1/PD-L1 inhibitor monotherapy exhibits poor efficacy in advanced HCC and NSCLC with liver metastases. Emerging data suggests that advanced HCC and NSCLC with liver metastases may be uniquely sensitive to combination therapy with atezolizumab-bevacizumab. The liver microenvironment possesses unique immunologic characteristics that may underpin this responsiveness but are presently poorly characterized.

Full Text